SUSP1 antagonizes formation of highly SUMO2/3-conjugated species
View/ Open
Issue Date
2006-09-21Author
Mukhopadhyay, Debaditya
Ayaydin, Ferhan
Kolli, Nagamalleswari
Tan, Shyh-Han
Anan, Tadashi
Kametaka, Ai
Azuma, Yoshiaki
Wilkinson, Keith D.
Dasso, Mary
Publisher
The Rockefeller University Press
Type
Article
Article Version
Scholarly/refereed, publisher version
Metadata
Show full item recordAbstract
Small ubiquitin-related modifier (SUMO) processing and deconjugation are mediated by sentrin-specific proteases/ubiquitin-like proteases (SENP/Ulps). We show that SUMO-specific protease 1 (SUSP1), a mammalian SENP/Ulp, localizes within the nucleoplasm. SUSP1 depletion within cell lines expressing enhanced green fluorescent protein (EGFP) fusions to individual SUMO paralogues caused redistribution of EGFP-SUMO2 and -SUMO3, particularly into promyelocytic leukemia (PML) bodies. Further analysis suggested that this change resulted primarily from a deficit of SUMO2/3-deconjugation activity. Under these circumstances, PML bodies became enlarged and increased in number. We did not observe a comparable redistribution of EGFP-SUMO1. We have investigated the specificity of SUSP1 using vinyl sulfone inhibitors and model substrates. We found that SUSP1 has a strong paralogue bias toward SUMO2/3 and that it acts preferentially on substrates containing three or more SUMO2/3 moieties. Together, our findings argue that SUSP1 may play a specialized role in dismantling highly conjugated SUMO2 and -3 species that is critical for PML body maintenance.
Description
This is the publisher's version, also available electronically from http://jcb.rupress.org/content/174/7/939
ISSN
0021-9525Collections
Citation
Mukhopadhyay, Debaditya et al. (2006). "SUSP1 antagonizes formation of highly SUMO2/3-conjugated species." Journal of Cell Biology, 174(7):939-949. http://www.dx.doi.org/10.1083/jcb.200510103
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.